Plasma pTau217 is not only useful to assist early and accurate diagnosis of AD but may also contribute to prognosis and more tailored selection for Aβ monoclonal antibody therapies where benefit appears reduced in persons with advanced tau aggregation. Here, MAPT is linked to Alzheimer disease.